Antithrombotic Treatment of Embolic Stroke of Undetermined SourceHans‐Christoph Diener, Wolf-Rüdiger Schäbitz, Ralph L. Sacco et al.|Stroke|2020Cited by 34
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) studyPaolo Verdecchia, Giuseppe Di Pasquale, Eva Kleine et al.|EP Europace|2017Cited by 19
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ studyCharles V. Pollack, Jeffrey I. Weitz, Anastasia Ustyugova et al.|Journal of Medical Economics|2016Cited by 11